Viracta Therapeutics (VIRX)

Viracta Therapeutics (VIRX) Income Statement


Viracta Therapeutics Income Statement

Last quarter (Q3 2023), Viracta Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Viracta Therapeutics's net income was $-12.60M. See Viracta Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21
Total Revenue
Cost of Revenue
Gross Profit
Operating Expense
$ 25.56M$ 50.59M$ 114.28M
Operating Income
$ -48.71M$ -50.59M$ -114.28M
Net Non Operating Interest Income Expense
$ 288.00K$ 594.00K$ -453.00K
Other Income Expense
$ -932.00K$ -620.00K$ 33.00K
Pretax Income
$ -47.49M$ -49.38M$ -114.76M
Tax Provision
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -47.51M$ -49.38M$ -114.76M
Basic EPS
$ -1.52$ -1.30$ -3.60
Diluted EPS
$ -1.99$ -1.30$ -3.60
Basic Average Shares
$ 153.49M$ 37.79M$ 31.87M
Diluted Average Shares
$ 153.49M$ 37.79M$ 31.87M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 25.56M$ 50.59M$ 114.28M
Net Income From Continuing And Discontinued Operation
$ -47.60M$ -49.20M$ -114.76M
Normalized Income
$ -9.88M$ -39.01M-
Interest Expense
$ -46.11M$ -48.80M$ -114.31M
$ -47.20M$ -49.21M$ -114.13M
Currency in USD

Viracta Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis